• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Annual general meeting of Prolight Diagnostics AB (publ) on 26 May 2026

PRLDRegulatory press release26.05.2026 klo 17.30
Discuss
Download the release

The annual general meeting (AGM) of Prolight Diagnostics AB (publ) took place on 26 May 2026 in Stockholm. Full information regarding the decisions of the AGM is available on the company’s website, www.prolightdx.com. The AGM resolved in accordance with all of the motions presented in the notification of the AGM except for the election of the chairman for the meeting and determination on the remuneration to the board members.

Resolution regarding the adoption of the income statement and the balance sheet, as well as discharge from liability
The AGM resolved to adopt the income statement and the balance sheet for the parent company and the group for the previous financial year. The board of directors and the managing director were discharged from liability for the same period.

Resolution on the appropriation of the company’s result in accordance with the adopted balance sheet
The AGM resolved that no dividend be paid for the previous financial year, and that the result will be carried forward. 

Board of directors
The AGM resolved that the board of directors shall consist of six board members with no deputies. Ulf Bladin, Steve Ross, Aileen McGettrick, Tobias Volker, Kiarash Farr and Fredrik Alpsten were re-elected as board members. Fredrik Alpsten was re-elected as chairman of the board.

Resolution pertaining to directors’ fees
The AGM resolved that a fee of SEK 400,000 be allocated to the chairman of the board and that a fee of SEK 240,000 be allocated to each of the other board members. The said fees include remuneration for committee work, if applicable. A board member who is employed by the company or any of its subsidiaries shall not receive a fee.

Auditor
The AGM resolved to re-elect the registered accounting firm, Forvis Mazars AB, as the company’s auditor until the end of the next AGM. The authorised auditor, Jesper Ahlkvist, will serve as the auditor in charge. Fees to the auditor are paid against approved invoices.

Authorisation of the Board of Directors to resolve on issue of shares, warrants and/or convertible instruments
The AGM resolved, in accordance with the board’s proposal, to authorise the board to, on one or several occasions during the period until the next AGM and within the limits of the articles of association, issue new shares, warrants, and/or convertibles. The board of directors is authorised to issue new shares, warrants, and/or convertibles with deviation from the shareholders’ pre-emption rights and/or provisions for contribution in kind, set-off or other conditions.

For further information, please contact:
Ulf Bladin, CEO
E-mail: info@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com

About Us
Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.
 
The company’s share is traded on the NGM Growth Market marketplace, under the ticker PRLD.

Attachments
Annual general meeting of Prolight Diagnostics AB (publ) on 26 May 2026